Analysis of Q10 Coenzyme Efficacy for Long-term Treatment of Cyclic Vomiting Syndrome in Children
Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Sep 25, 2017
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Cyclic vomiting syndrome as defined by Rome IV criteria
- • Treated with Q10 coenzyme treatment for cyclic vomiting syndrome
- • Q10 coenzyme treatment started between January 2000 and July 2006
- Exclusion Criteria:
- • - Refusal of processing of personal data reported in patient medical files
About Central Hospital, Nancy, France
Central Hospital, located in Nancy, France, is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes. As a prominent clinical trial sponsor, the hospital is committed to conducting innovative studies across various therapeutic areas, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, Central Hospital leverages its state-of-the-art facilities and expertise to contribute to the development of cutting-edge treatments and enhance the overall quality of care within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vandoeuvre Les Nancy, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials